Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ticarcillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | RECQL | P46063 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 1/20 | 0.61 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 1/20 | 0.59 |
| ▸ | RARG | P13631 | 1/20 | 0.59 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.59 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ticarcillin SCHEMBL27742456 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935398 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4228859 | 1.00 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL5047437 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL34025 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738099 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL10738085 | 0.99 | PTGS1 (1.00) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL28757995 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL9929365 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 | |
| Ticarcillin SCHEMBL4935408 | 0.98 | PTGS1 (0.98) | PTGS1SMN1; SMN2KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1565 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074503-A | Composite bacteriostatic agent and application thereof in open tissue culture of plants | — | 2026-05-26 | — | — | CN | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| CN-119552154-A | Preparation method of ticarcillin sodium side chain 3-ATMA | 山西双雁药业有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-119350365-A | Synthesis method of ticarcillin sodium | 山西双雁药业有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| CN-117567484-A | Spherical potassium clavulanate, preparation method thereof and composite preparation | 华北制药集团先泰药业有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-114159432-B | Tebucillin sodium clavulanate potassium pharmaceutical composition and preparation method thereof | 成都倍特药业股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| CN-1615856-A | Antiseptic composition of sodium ticarcillin for injection | XIAO GUANGCHANG (CN) | 2005-05-18 | — | — | CN | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6245735-B1 | CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2001-06-12 | — | — | US | claimed |
| EP-0804220-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A SALT OF CLAVULANIC ACID, VANCOMYCIN AND ONE OR MORE BETA-LACTAM ANTIBIOTICS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-05 | — | — | EP | claimed |
| WO-1996022105-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A SALT OF CLAVULANIC ACID, VANCOMYCIN AND ONE OR MORE BETA-LACTAM ANTIBIOTICS | SMITHKLINE BEECHAM PLC (GB) | 1996-07-25 | — | — | WO | claimed |
| EP-0277008-A1 | Process for crystallization of potassium clavulanate | BEECHAM GROUP PLC (GB) | 1988-08-03 | — | — | EP | claimed |
| US-4444754-A | SYNERGISTIC WITH PENICILLIN | BEECHAM GROUP LIMITED (GB) | 1984-04-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | PTGS1 1195/4885SMN1; SMN2 1450/4885KDM4E 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.